Healthcare Industry News: Rapid Medical
News Release - September 26, 2006
Biosite Moves European Headquarters to SwitzerlandSAN DIEGO and MORGES, Switzerland, Sept. 26 (HSMN NewsFeed) -- Biosite® Incorporated (Nasdaq: BSTE ), a research-based provider of novel, Rapid Medical diagnostics, today announced the opening of its new headquarters for its European operations in Morges, Switzerland, near Geneva. The new headquarters will manage the Company's sales, marketing and customer support activities in Europe.
"Biosite's presence in the European market has grown dramatically since we opened our first international office in France in 2003," said Gary King, vice president, international operations. "The growth in our direct sales operations in Europe requires a strategically located facility to support our business strategy, particularly in the areas of marketing, clinical and customer support."
The new mailing address is:
Biosite International Sarl
Rue des Vignerons, 1A
Morges 1110, Switzerland
Tel: +41 21 566 70 50
Fax: +41 21 802 09 33
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite's Triage® rapid diagnostics are used in more than 50 percent of U.S. hospitals and in more than 60 international markets. Information on Biosite can be found at www.biosite.com.
This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Examples of forward-looking statements are financial targets and growth objectives and also include but are not limited to statements that are preceded by, followed by, or that include the words "will;" "believes;" "should;" "intend;" "anticipates;" "plans;" "expects;" "estimates;" or similar statements. Forward-looking statements in this press release include statements regarding Biosite's presence in the European market and anticipated growth in sales, marketing, clinical and customer support functions in Europe. Risks and uncertainties include risks associated with Biosite's ability to obtain regulatory approvals and complete other pre-market activities needed to launch new products as currently planned, including the MPO test, a sepsis panel, a panel for acute kidney injury and a Protein C test; Biosite's ability to effectively promote and achieve market acceptance of any new products; the continued growth of the BNP market generally, including the physician office market; and other risks associated with changing market conditions and the effect of competition from companies with greater capital and resources. Other risks that should be considered are detailed in the Company's most recent Annual Report on Form 10-K and other SEC filings. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Copies of the Company's SEC filings are available from the Investor Relations department or from the Company's website.
Biosite®, Triage® and New Dimensions in Diagnosis® are registered trademarks of Biosite Incorporated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.